Scientific publications

Научные публикации

  1. Prognostic value of FACT.pdf
  2. Level of FACT defines the transcriptional landscape.pdf
  3. FACT is a sensor of DNA torsional stress.pdf
  4. Preclinical Validation.pdf
  5. Anticancer drug candidate CBL0137.pdf
  6. Dermawan JK, Hitomi M, Silver DJ, Wu Q, Sandlesh P, Sloan AE, Purmal AA, Gurova KV, Rich JN, Lathia JD, Stark GR, Venere M. Pharmacological targeting of the histone chaperone complex FACT preferentially eliminates glioblastoma stem cells and prolongs survival in preclinical models. Cancer Res. 2016 Feb 26. pii: canres.2162.2015.
  7. Dermawan JK, Gurova K, Pink J, Dowlati A, De S, Narla G, Sharma N, Stark GR. Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-κB, and cell-cycle progression in non-small cell lung cancer. Mol Cancer Ther. 2014 Sep;13(9):2203-14. doi: 10.1158/1535-7163.MCT-14-0013. Epub 2014 Jul 15.
  8. Carter D., Murray J., Cheung B., Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma//Science Translational Medicine, 2015, 7(312)
  9. Burkhart, C., Fleyshman, D., Kohrn, R., Commane, M., Garrigan, J., Kurbatov, V., Toshkov, I., Ramachandran, R., Martello, L., and Gurova, K. V. (2014) Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer. Oncotarget 5, 11038-11053.
  10. Garcia H., Miecznikowski J., Safina A., Commane M., Ruusulehto A., Kilpinen S., Leach R., Attwood K., Li Y., Degan S., Omilian A., Guryanova O., Papantonopoulou O., Wang J., Buck M., Liu S., Morrison C., and Gurova K. // Facilitates Chromatin Transcription Complex is an ‘‘Accelerator’’ of Tumor Transformation and Potential Marker and Target of Aggressive Cancers // Cell Reports, 2013, 4, 1–15.
  11. Koman I.E., Commane M., Paszkiewicz G., Hoonjan B., Pal S., Safina A., Toshkov I., Purmal A.A., Wang D.,  Liu S., Morrison C., Gudkov A.V., Gurova K.V. // Targeting FACT Complex Suppresses Mammary Tumorigenesis in Her2/neu Transgenic Mice// Cancer Prev Res (Phila).,  2012, 5(8), 1025-35.
  12. Gasparian A. V., Burkhart C.A., Purmal A.A., Brodsky L., Pal M., Saranadasa M., Bosykh D.A., Commane M., Guryanova O.A., Pal S., Safina A., Sviridov S., Koman I.E., Veith J., Komar A.A., Gudkov A.V., Gurova K.V. Curaxins: Anticancer Compounds that Simultaneously Suppress NF-kB and Activate p53 by Targeting FACT// Sci Transl Med., 2011, 3 (95), 95ra74.
  13. Giulio F. Draetta and Ronald A. DePinho. Cancer Drug Discovery Faces the FACT// Sci Transl Med., 2011, 3(95), 95-97.
  14. Garcia H., Fleyshman D., Kolesnikova R., Safina A., Commane M., Paszkiewicz G., Omelian A., Morrison K., Gurova K.  Expression of FACT in mammalian tissues suggests its role in maintaining of undifferentiated state of cells// Oncotarget, 2011, 2(10), 783-96.
  15. Guo C., Gasparian A.V., Zhuang Z., Bosykh D.A., Komar A.A., Gudkov A.V., Gurova K.V. 9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-kB and p53 pathways// Oncogene, 2009, 28(8), 1151-61.
  16. Neznanov N., Gorbachev A., Neznanova L., Komarov A., Gurova K., Gasparian A., Banerjee A., Almasan A., Fairchild R., Gudkov A. Anti-malaria drug blocks proteotoxic stress response: anti-cancer implications// Cell Cycle, 2009, 8(23) 3960-70.
  17. Gurova K. New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents// Future Oncology, 2009, 5 (10), 1685.
  18. Gurova K., Hill J., Guo C., Prokvolit A., Burdelya L., Samoylova E., Khodyakova A., Ganapathi R., Ganapathi M., Tararova N., Bosykh D., Lvovskiy D., Webb T., Stark G., Gudkov A. Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kB dependent mechanism of p53 supression in tumors// PNAS, 2005, 102 (48): 17448-17453.
  19. Gurova K., Hill J., Razorenova O., Chumakov P., Gudkov A. p53 pathway in renal cell carcinoma is repressed by a dominant mechanism// Cancer Res., 2004, 64(6), 1951-8.
You are here:   HomeScientific publications